share_log

HC Wainwright & Co. Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target

HC Wainwright & Co. Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target

HC Wainwright & Co.將 Oncternal Therapeutics 升級爲收購,宣佈目標價爲 2 美元
Benzinga ·  2023/09/18 06:31

HC Wainwright & Co. analyst Raghuram Selvaraju upgrades Oncternal Therapeutics (NASDAQ:ONCT) from Neutral to Buy and announces $2 price target.

HC Wainwright&Co.分析師Raghuram Selvaraju將Oncent Treateutics(納斯達克:ONCT)從中性上調至買入,並宣佈目標價2美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論